On Thursday, 23 July 2015, at 11AM Eastern Time (Washington, DC), KEI will host a seminar on drug pricing featuring Dr. Ruth Lopert, the Deputy Director of Pharmaceutical Policy and Strategy at the Center for Pharmaceutical Management, at Management Sciences for Health (MSH).
The seminar will take place at the KEI office in Dupont Circle, and up to 15 persons can be participate remotely, via a video Google Hangout link. There is also an option to participate via telephone. If there is a capacity issue for the remote participation by video, we will give priority to academics, government officials, NGOs working on drug pricing, and third party payers.
After the seminar, the discussion will be posted online via YouTube and will be available to the public for research and reference purposes.
Dr. Lopert will begin with a short presentation about the impact of the TPP on drug prices and also speak more broadly on how governments should set drug prices, and the types of information needed for this task.
Dr. Lopert was a key negotiator for the U.S.-Australian FTA and can provide key insights into this process and the potential implications of the TPP.
If you would like to participate, either through GoogleHangouts or in persion at our DC office, please fill out this Google Poll (http://goo.gl/forms/E9fXx4kQmH). Please contact Claire Cassedy via claire.cassedy[at]keionline.org with any additional questions. She will send out additional information regarding the seminar and instructions about joining the seminar on the morning of the event.
Dr. Lopert is currently the Deputy Director of Pharmaceutical Policy and Strategy at the Center for Pharmaceutical Management at MSG. She is also an adjunct professor in the Department of Health Policy at George Washington University and a consultant at the World Bank. Previously, Dr. Lopert was Principal Medical Adviser in Australia’s counterpart FDA agency, the Therapeutic Goods Administration and in 2006-07 was a Commonwealth Fund Harkness Fellow in Health Policy. She attended the University of Newcastle and the Australian National University and is the co-author of several papers regarding drug pricing.